Intrucept Biomedicine

Intrucept Biomedicine is a private biotechnology company focused on developing next-generation immunotherapies for cancer and autoimmune disorders. Founded by Dr. Lieping Chen, a pioneer in the discovery of the PD-1/PD-L1 pathway, the company specializes in targeting the VISTA (V-domain Ig suppressor of T cell activation) pathway. Their lead programs aim to overcome resistance to current checkpoint inhibitors by modulating VISTA's role in the tumor microenvironment. Intrucept leverages deep expertise in receptor-ligand interactions to design high-affinity antibodies with optimized therapeutic profiles. The company is headquartered in New Haven, Connecticut, maintaining close ties to academic research at Yale University.